These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19293790)

  • 1. Editorial: It's time to make organized colorectal cancer screening convenient and easy for patients.
    Levin TR
    Am J Gastroenterol; 2009 Apr; 104(4):939-41. PubMed ID: 19293790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants.
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Lieberman N; Klang S; Niv Y
    Am J Gastroenterol; 2009 Apr; 104(4):933-8. PubMed ID: 19293792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening.
    Clarke P; Jack F; Carey FA; Steele RJ
    Colorectal Dis; 2006 Jun; 8(5):389-92. PubMed ID: 16684082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based screening for colorectal cancer: Australian research and implementation.
    Young GP
    J Gastroenterol Hepatol; 2009 Oct; 24 Suppl 3():S33-42. PubMed ID: 19799696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stool test for colorectal cancer screening--it's time to move!
    Loitsch SM; Shastri Y; Stein J
    Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FIT: a valuable but underutilized screening test for colorectal cancer-it's time for a change.
    Allison JE
    Am J Gastroenterol; 2010 Sep; 105(9):2026-8. PubMed ID: 20818351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Care Ontario guaiac fecal occult blood test (FOBT) laboratory standards: evidentiary base and recommendations.
    Rabeneck L; Zwaal C; Goodman JH; Mai V; Zamkanei M
    Clin Biochem; 2008 Nov; 41(16-17):1289-305. PubMed ID: 18796300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer screening among first-degree relatives of colorectal cancer patients: benefits and barriers.
    Mack LA; Cook LS; Temple WJ; Carlson LE; Hilsden RJ; Paolucci EO
    Ann Surg Oncol; 2009 Aug; 16(8):2092-100. PubMed ID: 19479307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Feasibility of colorectal cancer screening with fecal occult blood test distributed by public pharmacies].
    Pippa G; Ferrara M; Valle S; Diego B; Alessandra B; Apuzzo M; Bazuro ME; Tammaro G; Federici A
    Recenti Prog Med; 2009; 100(7-8):348-51. PubMed ID: 19725474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Colorectal cancer screening: immunological test for faecal occult blood preferred].
    Jansen JB; van Rossum LG; Laheij RJ
    Ned Tijdschr Geneeskd; 2009; 153():A474. PubMed ID: 19785842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the patient with a positive fecal occult blood test, who at the same time is taking a nonsteroidal anti-inflammatory drug, require further evaluation to rule out a colorectal cancer?
    Babb RR
    J Clin Gastroenterol; 2005; 39(10):921. PubMed ID: 16208124
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunochemical fecal occult blood tests for colorectal cancer screening.
    Allison JE
    Am J Med; 2004 Apr; 116(7):498; author reply 498-9. PubMed ID: 15047043
    [No Abstract]   [Full Text] [Related]  

  • 13. Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study.
    Friis S; Poulsen AH; Sørensen HT; Tjønneland A; Overvad K; Vogel U; McLaughlin JK; Blot WJ; Olsen JH
    Cancer Causes Control; 2009 Jul; 20(5):731-40. PubMed ID: 19122977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dually eligible and colorectal cancer screening: too little, too late?
    Carcaise-Edinboro P; Bradley CJ; Dahman B
    J Health Care Poor Underserved; 2009 Aug; 20(3):854-65. PubMed ID: 19648712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in colorectal cancer test use in the medicare population, 1998-2005.
    Schenck AP; Peacock SC; Klabunde CN; Lapin P; Coan JF; Brown ML
    Am J Prev Med; 2009 Jul; 37(1):1-7. PubMed ID: 19423273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non steroidal anti-inflammatory drugs (NSAIDs) - balancing gastrointestinal complications and the cardiovascular risk].
    Kandulski A; Venerito M; Malfertheiner P
    Dtsch Med Wochenschr; 2009 Aug; 134(33):1635-40; quiz 1641-4. PubMed ID: 19650027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer mass screening event utilising quantitative faecal occult blood test.
    Chew MH; Suzanah N; Ho KS; Lim JF; Ooi BS; Tang CL; Eu KW
    Singapore Med J; 2009 Apr; 50(4):348-53. PubMed ID: 19421676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening.
    Takai T; Kanaoka S; Yoshida K; Hamaya Y; Ikuma M; Miura N; Sugimura H; Kajimura M; Hishida A
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1888-93. PubMed ID: 19505922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Screening for colorectal cancer in high-risk and intermediate-risk subject: what's the best tool?].
    Trevisani L; Cifalà V; Sartori S; Tombesi P; Matarese V; Pezzoli A; Abbasciano V
    Recenti Prog Med; 2009 Feb; 100(2):68-72. PubMed ID: 19350797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal cancer screening - using informatics and compunetics to empower the at-risk individual.
    Aramini JJ; Zhang X; Popovich ML
    Stud Health Technol Inform; 2008; 137():42-8. PubMed ID: 18560066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.